ArticleJournal of molecular histology2026
Lidocaine alleviates diabetic neuropathic pain by inhibiting spinal astrocyte activation through modulation of the CXCL13/CXCR5 axis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This study aimed to investigate the analgesic effects of lidocaine (Lido) on diabetic neuropathic pain (DNP), a common complication of diabetes, and to elucidate the underlying mechanism. A DNP mouse model was established by a single streptozotocin injection at 200 mg/kg. Two weeks later, mice received intraperitoneal infusion with 2% Lido for 7 consecutive days. The analgesic effect of Lido was assessed by pain behavioral tests. Astrocyte activation, pro-inflammatory cytokine levels, and CXCL13 and CXCR5 expression were examined in mechanistic studies. Lido significantly improved mechanical allodynia and thermal hyperalgesia in DNP mice. Lido reduced spinal astrocyte activation and pro-inflammatory cytokine levels in DNP mice. It also inhibited CXCL13 and CXCR5 expression, with their upregulation diminishing Lido's analgesic effects. Lido alleviates DNP by inhibiting spinal astrocyte activation via modulation of the CXCL13/CXCR5 axis.
Indexed as
Identifiers
42098528What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.